Lung/Bronchial NETs

PRRT/RLT Trials

• 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

• Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs

• Alpha PRRT with Pb-212 (all NET)

• Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC 

• Alpha PRRT with Pb-212 VMT

• Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC

• Lu-177 DOTATATE + Cabozantanib (all NET)

• Lu-177 DOTATATE vs Everolimus in Lung NETs

Immunotherapies

• DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers

• DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)

• IL13Rα2 CAR T Cell Study for Solid Tumor Cancers

• Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs

• Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Targeted Therapies

• Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

• BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors

• Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs)

• STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors

• Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms